| Biomarker ID | 1103 |
| PMID | 23582881 |
| Year | 2013 |
| Biomarker | Apolipoprotein B |
| Biomarker Basis | Concentration Based |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Upregulated in Progression Free Survival |
| Odds Ratio/Hazard Ratio/Relative Risk | HR: 2.78 (1.19–6.25) |
| Effect on Pathways | NA |
| Experiment | Progression Free Survival (PFS) at 12 weeks |
| Type of Biomarker | Prognostic |
| Cohort | A total of 37 chemotherapy-naive patients with mCRPC and progressive disease were recruited to this study |
| Senstivity | 85% |
| Specificity | 80% |
| AUC | 0.785 |
| Accuracy | 82% |
| Level Of Significance | p = 0.01 |
| Method Used | NA |
| Clinical | Yes |
| Remarks | The primary end point was progression- free survival (PFS) at 12 weeks: defined as the absence of prostate-specific antigen (PSA), radiographic progression, or clinical progression. |
| Clinical Trial Number | NCT00976755 |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |